Replimune gets slapped with a second FDA CRL

Another red light from the FDA

Replimune just got hit with a second complete response letter from the FDA for RP1, its lead asset being developed with Bristol Myers’ Opdivo in advanced melanoma. That’s regulatory speak for: not yet, try again.

Why this stings

The market reaction was brutal — shares sank 63% in premarket trading — because a CRL doesn’t just delay a drug, it can reset the whole timeline. And when it’s the second one? Investors start wondering whether this train is ever leaving the station.

For Replimune, the issue is bigger than one approval decision:

• the accelerated-approval path just got shakier
• the company may need more data, more time, or both
• every delay burns cash and patience, which is a rough combo for a biotech name

The Bristol Myers angle

BMY is mentioned here because RP1 is being studied alongside Opdivo, but the regulatory headache lands squarely on Replimune’s shoulders. Still, whenever a combo therapy gets bounced by regulators, the partner drug gets pulled into the story like an innocent friend who just wanted fries.

Big picture

Biotech is basically a game of cliffhangers, and this one ended with the FDA saying “come back later.” Until Replimune can clear the regulatory bar, investors are left holding a very expensive maybe.